Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

D. van der Heijde, A. Deodhar, R. Fleischmann, P. J. Mease, M. Rudwaleit, T. Nurminen, O. Davies

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint Dive into the research topics of 'Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis'. Together they form a unique fingerprint.

Medicine & Life Sciences